CCA
ALXN

Childress Capital Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Childress Capital Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-110
Closed -$17K – 1076
2020
Q4 		$17K Buy
+110
New +$14.1K 0.01% 401

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Childress Capital Advisors's ALXN Position: Q1 2021 in Review

Childress Capital Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 110 shares — an estimated $17K sold.

Childress Capital Advisors first reported a position in ALXN in Q4 2020 and held it in 1 quarter. The position peaked at $17K in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Childress Capital Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Childress Capital Advisors sold 110 Alexion Pharmaceuticals shares in Q1 2021, an estimated $17K.
  • Childress Capital Advisors first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Childress Capital Advisors's Alexion Pharmaceuticals position peaked at $17K in Q4 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Childress Capital Advisors's 13F filing for Q1 2021, filed 21 May 2021.